
US pharmaceutical giant AbbVie has agreed to invest up to $2.54 billion in a partnership with Germany-based biotechnology company Disco Pharmaceuticals to develop next-generation cancer treatments. The deal focuses on developing bispecific antibody therapies for solid tumours, an emerging class of cancer medicines designed to target two proteins simultaneously. Disco will receive $40 million upfront, along with potential milestone payments of up to $2.5 billion and tiered royalties on worldwide sales.
The partnership will focus on developing so-called AND-gated bispecific therapeutics, which are designed to recognise cancer cells only when two specific target proteins are present together. This approach could help minimise damage to healthy tissues while improving the precision of cancer treatment. Disco will lead the research and discovery process, while AbbVie will have exclusive licensing rights to selected programmes for further development. The company is currently exploring applications in small-cell lung and colorectal cancers, with a development candidate expected to be selected in the second half of 2027.
The agreement marks another significant move by AbbVie into the rapidly growing bispecific antibody market, where major pharmaceutical companies such as Bristol Myers Squibb, Pfizer and Merck are also expanding their investments. Earlier this year, AbbVie paid $650 million upfront to China’s RemeGen for rights outside China to an experimental bispecific treatment targeting solid tumours. The latest partnership highlights growing industry interest in precision-based cancer therapies and the potential of next-generation antibody treatments.
Pic Courtesy: google/images are subject to copyright









